TY - JOUR
T1 - The competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 attenuates the rate-decreasing effects of NMDA in rhesus monkeys without producing ketamine-like discriminative stimulus effects
AU - France, Charles P.
AU - Woods, James H.
AU - Ornstein, Paul
N1 - Funding Information:
The authors are grateful to L. Konrad for technical assistance and to R.J. McLaughlin and D. Robinson for assistance in preparing the manuscript. This research was supported by USPHS Grant DA-06325.
PY - 1989/1/10
Y1 - 1989/1/10
N2 - The purported competitive excitatory amino acid antagonist CGS 19755 was compared to the non-competitive antagonists ketamine and MK-801 in three rhesus monkeys discriminating between 1.78 mg/kg of ketamine and saline while responding under a fixed-ratio 100 schedule of food presentation. MK-801 substituted completely for the ketamine discriminative stimulus and was 32 times more potent than ketamine as a discriminative stimulus. CGS 19755 was studies using sinlge and cumulative dosing procedures up to a dose of 10.0 mg/kg; for all conditions, CGS 19755 produced responding exclusively on the saline lever and had only modest rate-decreasing effects. N-Methyl-D-aspartate administered alone also did not produce ketamine-appropriate responding but did decrease response rates in a dose-related manner. N-Methyl-D-aspartate eliminated responding in all monkeys at doses of 5.6-10.0 mg/kg. MK-801 and ketamine antagonized the rate-decreasing effects of N-methyl-D-asparate, however, ketamine was most effective as an antagonist at doses that decreased response effects of N-methyl-D-asparate, however, ketamine was most the rate-decreasing effects of N-methyl-D-aspartate and shifted the N-methyl-D-aspartate dose-effect curve more than 5-fold to the right. The magnitude of antagonism of N-methyl-D-aspartate appeared to be somewhat greater with CGS 19755 than with MK-801 or ketamine. Thus, a competitive (CGS 19755) and some non-competitive (MK-801 and ketamine) excitatory amino acid antagonists can attenuate the rate-decreasing effects of N-methyl-D-aspartate. Surprisingly, the results suggest that antagonism of N-methyl-D-aspartate is not sufficient to produce ketamine-like discriminative stimulus effects under these conditions in rhesus monkeys.
AB - The purported competitive excitatory amino acid antagonist CGS 19755 was compared to the non-competitive antagonists ketamine and MK-801 in three rhesus monkeys discriminating between 1.78 mg/kg of ketamine and saline while responding under a fixed-ratio 100 schedule of food presentation. MK-801 substituted completely for the ketamine discriminative stimulus and was 32 times more potent than ketamine as a discriminative stimulus. CGS 19755 was studies using sinlge and cumulative dosing procedures up to a dose of 10.0 mg/kg; for all conditions, CGS 19755 produced responding exclusively on the saline lever and had only modest rate-decreasing effects. N-Methyl-D-aspartate administered alone also did not produce ketamine-appropriate responding but did decrease response rates in a dose-related manner. N-Methyl-D-aspartate eliminated responding in all monkeys at doses of 5.6-10.0 mg/kg. MK-801 and ketamine antagonized the rate-decreasing effects of N-methyl-D-asparate, however, ketamine was most effective as an antagonist at doses that decreased response effects of N-methyl-D-asparate, however, ketamine was most the rate-decreasing effects of N-methyl-D-aspartate and shifted the N-methyl-D-aspartate dose-effect curve more than 5-fold to the right. The magnitude of antagonism of N-methyl-D-aspartate appeared to be somewhat greater with CGS 19755 than with MK-801 or ketamine. Thus, a competitive (CGS 19755) and some non-competitive (MK-801 and ketamine) excitatory amino acid antagonists can attenuate the rate-decreasing effects of N-methyl-D-aspartate. Surprisingly, the results suggest that antagonism of N-methyl-D-aspartate is not sufficient to produce ketamine-like discriminative stimulus effects under these conditions in rhesus monkeys.
KW - (Rhesus monkey)
KW - CGS 19755 (1-(cis-2-carboxypiperidine-4-yl)-methyl-1-phosphonic acid)
KW - Drug discrimination
KW - MK-801
KW - NMDA (N-methyl-D-aspartate)
KW - Schedule-controlled responding
UR - http://www.scopus.com/inward/record.url?scp=0024520340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024520340&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(89)90697-3
DO - 10.1016/0014-2999(89)90697-3
M3 - Article
C2 - 2651134
AN - SCOPUS:0024520340
SN - 0014-2999
VL - 159
SP - 133
EP - 139
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2
ER -